Oct 2026· Pharmaceuticals· Vol 19· 0 citations· 53 references
Medicine
TL;DR
In this retrospective uncontrolled cohort, reductions in headache frequency and other clinical improvements were observed during BoNTA treatment in patients with CM and HFEM, and these findings cannot establish the efficacy of BoNTA in HFEM.
Abstract
Background/Objectives. Although onabotulinumtoxinA (BoNTA) is an established therapy for chronic migraine (CM), its effectiveness in high-frequency episodic migraine (HFEM) remains uncertain. We conducted an 18-year, single-center, retrospective study of patients treated with BoNTA for CM or HFEM. Methods. We included 136 patients with CM and 71 with HFEM who had previously received multiple oral preventive therapies, who received BoNTA using an injection paradigm based on the PREEMPT protocol. Clinical and laboratory data were collected. Results. Responder rates, defined as a ≥50% reduction in monthly headache days, were 65.4% in CM and 71.8% in HFEM. Both groups showed a significant reduction in the frequency of headache days and headache intensity and improved response to symptomatic treatment. The mean duration of benefit among responders was 3.66 (SD 2.12) months in CM and 3.78 (SD 1.11) months in HFEM. No statistically significant associations were detected between responder status and either the duration of previous preventive treatment or the neutrophil-to-lymphocyte ratio. Responders with CM showed a non-significant tendency to have used a lower number of preventive treatments compared with partial responders plus non-responders. At the end of follow-up, 42.6% of CM and 57.8% of HFEM patients remained on BoNTA. Conclusions. In this retrospective uncontrolled cohort, reductions in headache frequency and other clinical improvements were observed during BoNTA treatment in patients with CM and HFEM. Because this study lacked a control group, these findings cannot establish the efficacy of BoNTA in HFEM and should be interpreted as exploratory.
The study concludes that administering 200 U of OnaBT-A, significantly decreases the frequency and duration of headaches when compared to 155 U, and recommends considering this dosage for patients who do not accomplish adequate relief with 155 U of OnaBT-A.
W. Alkhaffaf, M. Alkataan· Georgian medical news· 0 citations
In this Romanian real-world cohort, anti-CGRP monoclonal antibody treatment was associated with substantial reductions in migraine/headache frequency in patients with HFEM and CM, and generally well-tolerated.
Alin Ciubotaru, Albert Vamanu, Cristina Grosu et al.· Biomedicines· 0 citations
BackgroundCluster headache (CH) is a highly disabling primary headache disorder characterized by severe unilateral attacks occurring in bouts. Calcitonin gene-related peptide plays a key role in CH pathophysiology, yet preventive treatment options remain limited. We aimed to evaluate the short-term clinical effects of...
Background Chronic migraine is a chronic disabling neurological disease and has a significant impact on quality of life. Topiramate and amitriptyline are commonly used for migraine prevention, but treatment decisions should consider their effectiveness and safety profiles. This study aimed to compare the effectiveness...
M. Karami, Amber Hassan, Amal M. Alkhotani et al.· Frontiers in Pain Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.